SPRAVATO Treatment

Explore novel ways to heal treatment resistant depression with esketamine(SPRAVATO) treatment

Summary: Spravato, also known as esketamine, is a treatment option for individuals with treatment-resistant depression (TRD) and major depressive disorder with acute suicidal ideation/behavior. Kadima Neuropsychiatry offers Spravato treatment for depression in San Diego and was the first clinic to be certified to provide it. Spravato treatment is administered as a nasal spray and works by quickly increasing the levels of a neurotransmitter called glutamate in the brain, which can lead to an improvement in mood. Spravato is typically used in conjunction with an oral antidepressant and has been shown to have a rapid onset of action, with some patients experiencing relief from symptoms within 24 hours. Additionally, Spravato has been shown to have a lower risk of side effects compared to traditional antidepressants. Spravato is only available through a restricted distribution system and administered in certified medical offices by trained medical staff in San Diego, CA. It’s an FDA approved treatment for treatment-resistant depression and is covered my most insurances. Spravato treatment is a game-changer for those who suffer from treatment resistant depression and major depressive disorder with acute suicidal ideation/behavior and have not found relief with traditional antidepressants.

WHAT is Spravato?

Esketamine, also known by the brand name Spravato, is a medication that has recently been approved for the treatment of depression in adults who have not responded to other forms of treatment. It is the first new type of antidepressant to be approved by the US Food and Drug Administration (FDA) in decades, and it has shown promise in helping people with treatment-resistant depression.

Esketamine is a form of ketamine, which has been used for decades as an anesthetic in medical and veterinary settings. Ketamine works by altering the levels of certain chemicals in the brain, which can have a rapid and dramatic effect on mood. Esketamine is thought to work in a similar way, but it is more targeted and has a longer-lasting effect than regular ketamine.

HOW Is SPravato treatment Given?

One of the unique features of esketamine is that it is administered via a nasal spray. It is given in a doctor’s office or clinic and is taken twice a week. The treatment involves a series of four to six treatments, followed by maintenance treatments as needed.

Esketamine is only available at clinics and by medical providers who have been certified to offer this treatment. Kadima was the first clinic to provide Spravato treatment in San Diego. It was the first to be certified by Johnson & Johnson to offer this medication. Dr. Feifel and the rest of our ketamine therapists are highly experienced at administering this antidepressant medication.

Benefits of SPRAVATO Treatment

Fast acting relief

esketamine(SPRAVATO) treatment can start helping depression effects within the first treatment

High rate of success

Many studies have found that esketamine(SPRAVATO) has a significant, quick, and sustained effect on relieving symptoms of depression

Revolutionary Treatment

esketamine(SPRAVATO) is a revolutionary treatment for depression and provides hope for people with treatment-resistant depression

SPRAVATO Treatment for depression

Esketamine has been shown to be safe and effective in several large clinical trials for the treatment of depression. In one large study, a significant portion of people with treatment-resistant depression who received esketamine had a significant reduction in their symptoms, compared to placebo, within 24 hours of taking the medication.

In addition to being effective, esketamine was found to have relatively few side effects. The most common side effects of esketamine include transient nausea, dizziness, and dissociation (feeling detached from reality). However, dissociation is considered by many experts to be a key factor in the therapeutic antidepressant effect rather than a side effect. It can also sometimes cause changes in blood pressure and heart rate, so it is important to have close monitoring during treatment. In addition, esketamine is not recommended for people with a history of substance abuse or a current substance use disorder.

 

Experts in SPRAVATO Treatment​

“Recent data suggest that Ketamine, given intravenously, might be the most important breakthrough in antidepressant treatment in decades.” – Thomas Insel, MD, Director of the National Institute of Mental Health, 2002-2015

At Kadima’s clinic, we offer Spravato treatment for depression. If you or a loved one is struggling with treatment-resistant depression and are interested in exploring this treatment option, please don’t hesitate to contact us. Our team of mental health professionals will be happy to answer any questions you may have and help you determine if esketamine (Spravato) therapy is right for you.

David Feifel hosts Tom Insel and associate

Dr. David Feifel (C) with Dr. Tom Insel (R) and Dr. Paul Dagum (L) at Kadima

Frequently Asked Questions

Most frequent questions and answers

Spravato is administered as a nasal spray in certified medical offices by trained medical staff. It is typically used in conjunction with an oral antidepressant and is only available through a restricted distribution system

Coverage for Spravato treatment can vary depending on the individual’s insurance plan and provider. Call us at (858)412-4130 to see if your insurance covers it.

Spravato has been found to be generally safe for use in treating treatment resistant depression. However, it may cause some side effects, such as dizziness, nausea, and dissociation, which is why it is only available through a restricted distribution system and administered by trained medical staff.

Spravato, also known as esketamine, is FDA approved for the treatment of treatment-resistant depression (TRD) and major depressive disorder with acute suicidal ideation or behavior. To qualify for Spravato treatment, an individual typically must meet the following criteria:

  • Have been diagnosed with TRD or major depressive disorder with acute suicidal ideation or behavior
  • Have tried at least two different oral antidepressants at adequate doses and duration without sufficient improvement in symptoms
  • Be currently experiencing moderate to severe symptoms of depression despite ongoing treatment

It depends on the patient. Some patients will have noticeable improvement after the first treatment, while other patients may need a series of treatments before they see an improvement.

Both Spravato and ketamine are forms of ketamine therapy, but Spravato is a specific formulation that has been approved by the FDA for the treatment of treatment resistant depression. Ketamine is a generic version that is used off-label for the same purposes but not FDA approved for those specific conditions.

Are you interested in SPRAVATO treatment?

Our doctors will assess your conditions and see if you qualify for Esketamine (SPRAVATO) treatment
Call us for doctor assessment

Email: info@kadimanp.com

(858)412-4130